Cue BiopharmavsJohnson & Johnson

CUE and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

Cue Biopharma (CUE) has a market value of $30M and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, CUE moved -85.0% and JNJ +45.4%. Dividend yield: CUE none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CUE$30M

    JNJ$672B

    JNJ is 22,470 times CUE

  • Revenue, 12 months

    CUE$36M

    JNJ$99.3B

    JNJ is 2,787 times CUE

  • Net income, 12 months

    CUE-$207M

    JNJ$16.1B

  • Operating margin

    CUE-387.7%

    JNJ–

  • ROIC

    CUE-535.1%

    JNJ12.4%

    547.5 points apart

  • P/E

    CUE–

    JNJ41.7

  • Dividend yield

    CUE0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CUE-99.4%

    JNJ+97.0%

    196.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CUE-99.4%

JNJ+96.9%

010020020222023202420252026
Returns by period
PeriodCUEWith dividendsJNJWith dividends
1 year since November 14, 2025-85.0%Price -85.0%+45.4%Price +42.2%
3 years since November 17, 2023-96.1%-66.1% a yearPrice -96.1%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021-99.4%-64.6% a yearPrice -99.4%+97.0%+14.5% a yearPrice +71.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CUECue BiopharmaJNJJohnson & Johnson

Valuation

CUEJNJ
Valuation
Price$2.83$278.70
Market value$30M$672B
Enterprise value (EV)–$699B
P/E–41.7
P/E, 5-year median–21.9
P/B0.88.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

CUEJNJ
Results and growth
Revenue, 12 months$36M$99.3B
Net income, 12 months-$207M$16.1B
Free cash flow, 12 months-$51M$20.6B
Earnings per share, 12 months-$28.99$6.59
Revenue growth, year on year195.8%6.1%
Revenue growth a year, past+54.2%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CUEJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-387.7%–
Net margin-580.0%16.2%
ROIC-535.1%12.4%
ROE-1,013.2%19.7%

Balance sheet

CUEJNJ
Balance sheet
Cash$58M$17.2B
Total debt$0$44.7B
Net debt / EBITDA–1.1
Interest cover-1,381.7×18.0×

Dividends and buybacks

CUEJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CUE or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Cue Biopharma or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 22,470.4 times Cue Biopharma ($30M), at today's prices.

How did CUE and JNJ stock do over the last 5 years?

Since November 16, 2021, CUE's price moved -99.4% and JNJ's +71.3%. With dividends: CUE -99.4% (-64.6% a year), JNJ +97.0% (+14.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, CUE or JNJ?

The dividend yield at today's price is none for Cue Biopharma and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Cue Biopharma or Johnson & Johnson?

Over the last twelve months, the net margin was -580.0% for Cue Biopharma and 16.2% for Johnson & Johnson, and the operating margin -387.7% and –. Revenue was $36M and $99.3B.

Which is the better investment, Cue Biopharma or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.